Paragraphs
FORGING NEW PATHS IN DIABETES MANAGEMENT

FORGING NEW PATHS IN DIABETES MANAGEMENT

Now you can provide your patients with innovative CGM technology that can simplify their lives and provide better clinical outcomes. Eversense is the only CGM system with a 90-day, subcutaneous sensor – giving patients the longest wear time ever, along with unmatched convenience and accuracy.

sensor

transmitter

phone

calendar-icon

90-days sensor wear

vibe-alert

On-body vibe alerts

implantable

fully implantable sensor

sensors

4 sensor changes a year

vs. 26-52 for other CGM systems

target-icon

Exceptional accuracy

Especially in the 40-60 mg/dl range

Selector Id
section-transmitter-features
Selector Class
section-transmitter-features new-paths

UNMET NEEDS IN CGM TECHNOLOGY CAN CAUSE PATIENTS TO STRUGGLE WITH WEAR-TIME GOALS

Patients with diabetes receive clinical benefit from continuous glucose monitoring when the sensor is worn more than 80% of the time.1,2

80-percent

However, many patients struggle to meet this goal due to the limitations of traditional CGM technology:

  • short sensor life
  • accuracy issues
  • difficulties with sensor self-insertion and removal

As a result, only

1 out of 3 type 1 diabetes patients are currently using CGM.3
cgm users
1 out of 3 will discontinue use within a year.3
cgm-users-discontinuation
Selector Id
wear-time-goals
Selector Class
wear-time-goals

EVERSENSE DELIVERS UNMATCHED WEAR TIME AND IMPROVED GLYCEMIC OUTCOMES

The advanced sensor technology and under-the-skin sensor help patients reach unprecedented levels of wear time, leading to improved clinical outcomes.

Selector Id
glycemic-outcomes
Selector Class
glycemic-outcomes

With a 92% real-world wear time, Eversense exceeds both the 80% minimum threshold wear-time for clinical benefits and the 50-78% wear time for other CGMs.

chart

92%

Eversense CGM

chart

>80%

Required for optimal clinical benefit

chart

57%

Traditional CGMs

Selector Id
comparison
Selector Class
comparison
Exceptional Accuracy

Exceptional Accuracy

table

Selector Id
exceptional-accuracy
Selector Class
exceptional-accuracy
Highly accurate alert detection rates

Highly accurate alert detection rates

Within a 15-minute window, the Eversense CGM System uses threshold and predictive alerts to detect:

96%

of hypoglycemic events (70 mg/dL)

98%

of hyperglycemic events(180 mg/dL)

vibe alerts

In addition to visual and auditory alarms, Eversense’s unique predictive, on-body vibe alerts add an extra measure of safety, especially when patients are sleeping, or their mobile device is not close by.

Improved Clinical Outcomes

Multiple clinical trials have demonstrated that Eversense CGM use can reduce A1C levels.

graph
Selector Id
alarm-detection-rates
Selector Class
alarm-detection-rates

READY TO GET STARTED AS A PROVIDER?

Ready to prescribe Eversense CGM? Just fill out a simple form with a few details and we will contact you to answer questions and get you started.

Selector Id
section-transmitter-provider
Selector Class
section-transmitter-provider
wifi-icon
eversense-product

SENSOR

The 90-day fluorescent sensor is placed just under the skin in the upper arm and continuously measures glucose for up to 3 months.

bluethooth
transmitter

Transmitter

Water-resistant, rechargeable and removable, the transmitter sends data in near-real time to the user’s mobile device, and also provides on-body vibration alerts during glycemic swings.

 
iPhone

Mobile APP

Receives and displays glucose data in easy-to-read charts and graphs to show your patients if they are in or out of range. NO SEPARATE RECEIVER is required. Patients discreetly check their info on their personal iOS or Android mobile device or Apple Watch®.

Selector Id
section-transmitter-other-pages
Selector Class
section-transmitter-other-pages
Selector Class
section-lists
Sub Description